1. Home
  2. News
  3. Neuroscientific Biopharmaceuticals Ltd.
  4. Key Executive Appointments to Support Clinical Studies
More Neuroscientific Biopharmaceuticals Ltd. news
Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

Key Executive Appointments to Support Clinical Studies

Mar 30, 2021 at 9:38 PM EDT · Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · Mar 30, 2021 at 9:38 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/key-executive-appointments-to-support-clinical-studies

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Earlier from Neuroscientific Biopharmaceuticals

  • NSB to investigate treatment for post-COVID FibrosisNov 20, 2020
  • Strategic Placement to AlphaSwiss PartnersNov 11, 2020
  • Appendix 4E and Annual ReportAug 28, 2020
  • Updated Appendix 4CAug 11, 2020
  • Full Report from Multiple Sclerosis StudyAug 3, 2020

Later from Neuroscientific Biopharmaceuticals

  • Manufacturing UpdateApr 27, 2021
  • Appendix 4C - quarterlyApr 29, 2021
  • Update on Pivotal Ocular Safety StudiesMay 4, 2021
  • R&D Tax Rebate ReceivedMay 31, 2021
  • NSB partners with Linear Research for Phase I Clinical StudyJun 22, 2021
All Neuroscientific Biopharmaceuticals news releases↗

Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.

Follow Neuroscientific Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer